Athira Pharma, Inc. financial data

Symbol
ATHA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
18706 North Creek Parkway, Suite 104, Bothell, WA
Fiscal year end
December 31
Former names
M3 Biotechnology, Inc. (to 1/23/2019)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 433 % -48.4%
Debt-to-equity 30 % +141%
Return On Equity -116 % -88.5%
Return On Assets -88.9 % -63%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.7M shares +1.62%
Common Stock, Shares, Outstanding 38.7M shares +1.62%
Entity Public Float 96.3M USD -2.73%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.5M shares +1.22%
Weighted Average Number of Shares Outstanding, Diluted 38.5M shares +1.22%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 85M USD -0.42%
General and Administrative Expense 26.9M USD -21.1%
Costs and Expenses 114M USD -11.6%
Operating Income (Loss) -114M USD +11.6%
Nonoperating Income (Expense) 1.75M USD +468%
Net Income (Loss) Attributable to Parent -109M USD +9.38%
Earnings Per Share, Basic -2.85 USD/shares +10.1%
Earnings Per Share, Diluted -2.85 USD/shares +10.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68.9M USD -37.6%
Assets, Current 82M USD -54.1%
Property, Plant and Equipment, Net 2.69M USD -26%
Operating Lease, Right-of-Use Asset 871K USD -21.2%
Other Assets, Noncurrent 55K USD -93.3%
Assets 86.2M USD -53.3%
Accounts Payable, Current 388K USD -77.3%
Employee-related Liabilities, Current 4.44M USD +28%
Accrued Liabilities, Current 17M USD +2.47%
Liabilities, Current 27.8M USD -3.04%
Operating Lease, Liability, Noncurrent 912K USD -30.6%
Liabilities 28.7M USD -4.25%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3K USD
Retained Earnings (Accumulated Deficit) -391M USD -38.7%
Stockholders' Equity Attributable to Parent 57.6M USD -62.8%
Liabilities and Equity 86.2M USD -53.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.8M USD +1.49%
Net Cash Provided by (Used in) Financing Activities 99K USD -52.9%
Net Cash Provided by (Used in) Investing Activities 13M USD -63.3%
Common Stock, Shares Authorized 900M shares 0%
Common Stock, Shares, Issued 38.7M shares +1.62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.8M USD -235%
Deferred Tax Assets, Valuation Allowance 71.2M USD +65.7%
Deferred Tax Assets, Gross 71.8M USD +63%
Operating Lease, Liability 1.31M USD -21.4%
Depreciation 972K USD +0.94%
Payments to Acquire Property, Plant, and Equipment 5K USD -97.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -109M USD +8.58%
Lessee, Operating Lease, Liability, to be Paid 1.47M USD -24.4%
Property, Plant and Equipment, Gross 5.74M USD +0.32%
Operating Lease, Liability, Current 402K USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 509K USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 494K USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 158K USD -42.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 509K USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 31.3M USD +30.1%
Unrecognized Tax Benefits 3.11M USD +121%
Deferred Tax Assets, Net of Valuation Allowance 25.2M USD +136%
Share-based Payment Arrangement, Expense 11M USD +2.72%
Interest Expense 2K USD